Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N: EAU guidelines on prostate cancer. part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014, 65 (2): 467-479. 10.1016/j.eururo.2013.11.002.
Article
CAS
PubMed
Google Scholar
Abrahamsson PA: Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010, 57 (1): 49-59. 10.1016/j.eururo.2009.07.049.
Article
CAS
PubMed
Google Scholar
Taylor LG, Canfield SE, Du XL: Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009, 115 (11): 2388-2399. 10.1002/cncr.24283.
Article
PubMed
Google Scholar
Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, De Vos F, Huysse W, Ost P: Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014, in press
Google Scholar
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011, 59 (4): 572-583. 10.1016/j.eururo.2011.01.025.
Article
PubMed
Google Scholar
Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM: The role of 11C-choline and 18 F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013, 64 (1): 106-117. 10.1016/j.eururo.2013.04.019.
Article
PubMed
Google Scholar
Wondergem M, van der Zant FM, van der Ploeg T, Knol RJ: A literature review of 18 F-fluoride PET/CT and 18 F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013, 34 (10): 935-945. 10.1097/MNM.0b013e328364918a.
Article
CAS
PubMed
Google Scholar
Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P: Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013, 11 (1): 27-32. 10.1016/j.clgc.2012.08.003.
Article
PubMed
Google Scholar
Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A: Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2014, doi:10.1016/j.eururo.2014.02.011
Google Scholar
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008, 26 (7): 1148-1159. 10.1200/JCO.2007.12.4487.
Article
PubMed
PubMed Central
Google Scholar
Bottomley A, Flechtner H, Efficace F, Vanvoorden V, Coens C, Therasse P, Velikova G, Blazeby J, Greimel E, European Organisation for Research and Treatment of Cancer: Health related quality of life outcomes in cancer clinical trials. Eur J Cancer. 2005, 41 (12): 1697-1709. 10.1016/j.ejca.2005.05.007.
Article
CAS
PubMed
Google Scholar
EuroQol Group: EuroQol--a new facility for the measurement of health-related quality of life. the EuroQol Group. Health Policy. 1990, 16 (3): 199-208.
Article
Google Scholar
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003, 13 (3): 176-181. 10.1016/S1053-4296(03)00031-6.
Article
PubMed
Google Scholar
Mitropoulos D, Artibani W, Graefen M, Remzi M, Roupret M, Truss M: Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol. 2012, 61 (2): 341-349. 10.1016/j.eururo.2011.10.033.
Article
PubMed
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45 (2): 228-247. 10.1016/j.ejca.2008.10.026.
Article
CAS
PubMed
Google Scholar
Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ, European Society of Urogenital Radiology: ESUR prostate MR guidelines 2012. Eur Radiol. 2012, 22 (4): 746-757. 10.1007/s00330-011-2377-y.
Article
PubMed
PubMed Central
Google Scholar
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF: Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010, 37 (8): 4078-4101. 10.1118/1.3438081.
Article
PubMed
Google Scholar
Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR: Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012, 118 (11): 2962-2970. 10.1002/cncr.26611.
Article
PubMed
Google Scholar
Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, Gulisano M, Aterini S: Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011, 97 (1): 49-55.
CAS
PubMed
Google Scholar
Bedford JL, Lee YK, Wai P, South CP, Warrington AP: Evaluation of the Delta4 phantom for IMRT and VMAT verification. Phys Med Biol. 2009, 54 (9): N167-N176. 10.1088/0031-9155/54/9/N04.
Article
PubMed
Google Scholar
Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005, 23 (28): 7199-7206. 10.1200/JCO.2005.01.149.
Article
PubMed
Google Scholar
Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S: Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012, 12: 305-10.1186/1471-2407-12-305.
Article
CAS
PubMed
PubMed Central
Google Scholar
Palmbos PL, Hussain M: Non-castrate metastatic prostate cancer: have the treatment options changed?. Semin Oncol. 2013, 40 (3): 337-346. 10.1053/j.seminoncol.2013.04.007.
Article
PubMed
Google Scholar
Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, Drendel V, Schwardt M, Jandausch A, Schultze-Seemann W: Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol. 2012, 188 (6): 2190-2197. 10.1016/j.juro.2012.08.041.
Article
CAS
PubMed
Google Scholar
Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, Ratib O, Weber DC, Miralbell R: Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013, 52 (8): 1622-1628. 10.3109/0284186X.2013.764010.
Article
CAS
PubMed
Google Scholar
Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R: Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012, 82 (2): 889-897. 10.1016/j.ijrobp.2010.11.031.
Article
PubMed
Google Scholar